M
MYR
Biotech company developing and commercialising novel therapies for chronic hepatitis D
About MYR
MYR GmbH, a subsidiary of Gilead Sciences, Inc., is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for areas with significant unmet medical needs. The company operates in the global healthcare market, providing advanced therapeutic solutions to patients with life-threatening illnesses. MYR GmbH primarily serves healthcare providers, hospitals, and patients, leveraging its research and development capabilities to bring new treatments to market. The business model revolves around the development and commercialization of proprietary drugs, generating revenue through the sale of these medicines. By focusing on innovation and patient care, MYR GmbH aims to transform and simplify medical treatment for severe health conditions.
Source: Dealroom company dataNews
Open roles
MYR in the Bad Homburg ecosystem
The MYR office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A1 investor entered at this stage
Joint Journey
Series B and later2 investors entered at this stage
- ININSERM
- UHUniversity of Heidelberg
Source: Dealroom Talent Intelligence.
Global footprint
Patents
2 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See MYR on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


